Direct Lymphatic Immunotherapy for Metastatic Renal Cell Carcinoma

Our first published data in the immunotherapy of urological cancer with Interleukin- 2 (EL-2) date from 1984 when we observed for the first time tumor regression of infiltrating bladder cancer caused only by the intralesional injection of IL-2 [1].